Loading
TP
Theseus Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 19 Jul 2023.
Theseus Pharmaceuticals, Inc.: what insiders have been doing
This page follows insider dealings at Theseus Pharmaceuticals, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Nothing new has been filed by managers of Theseus Pharmaceuticals, Inc. in twelve months, the latest record being from 14 February 2024.
Looking back to 2021, when coverage begins, insiders filed 12 purchases and no sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
27
Thresholds
n/a
Buy Volume
€5M
12 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
Net income-US$43.6M
Last declaration on 14 February 2024
Declarations27 total
17,063,000 sharesCommon StockSEC:0001104659-24-023559:0
388,324 sharesCommon StockSEC:0001104659-24-023556:0
10,000 sharesCommon StockSEC:0001104659-24-023563:0
17,063,000 sharesCommon StockSEC:0001104659-24-023571:0
8,150.225 sharesCommon StockSEC:0001104659-24-023551:0
251,084 shares@ US$0.3289.6% of flowCommon StockSEC:0001745020-23-000060:0
328,482 shares@ US$3.0544.3% of flowCommon StockSEC:0000947871-23-000760:0
Canonical exit: 15 Oct 2023 (T+90)
523,450 shares@ US$2.9754.1% of flowCommon StockSEC:0001209191-23-042720:0
Canonical exit: 15 Oct 2023 (T+90)
328,482 shares@ US$3.0544.3% of flowCommon StockSEC:0000947871-23-000761:0
Canonical exit: 15 Oct 2023 (T+90)
250,000 shares@ US$5.0045.9% of flowCommon StockSEC:0001209191-23-000204:0
Canonical exit: 29 Mar 2023 (T+90)
100 shares@ US$5.00100.0% of flowCommon StockSEC:0001104659-23-000080:0
Canonical exit: 29 Mar 2023 (T+90)
1,502.189 shares@ US$6.65735.3% of flowCommon StockSEC:0001104659-22-123686:0
Canonical exit: 28 Feb 2023 (T+90)
2,500 shares@ US$6.79842.6% of flowCommon StockSEC:0001104659-22-118549:0
Canonical exit: 9 Feb 2023 (T+90)
192,000 shares@ US$5.2150.0% of flowCommon StockSEC:0000947871-22-001157:0
Canonical exit: 5 Feb 2023 (T+90)
192,000 shares@ US$5.2150.0% of flowCommon StockSEC:0000947871-22-001158:0
Canonical exit: 5 Feb 2023 (T+90)
11,521 shares@ US$9.975.0% of flowCommon StockSEC:0000947871-22-000088:0
Canonical exit: 19 Apr 2022 (T+90)
▲
Same trade as the filing by Carl l. Gordon, counted once · View ↗
11,521 shares@ US$9.975.0% of flowCommon StockSEC:0000947871-22-000087:0
Canonical exit: 19 Apr 2022 (T+90)
1,600 shares@ US$9.810.7% of flowCommon StockSEC:0000947871-22-000047:0
Canonical exit: 11 Apr 2022 (T+90)
▲
Same trade as the filing by Orbimed Advisors LLC, counted once · View ↗
1,600 shares@ US$9.810.7% of flowCommon StockSEC:0000947871-22-000050:0
Canonical exit: 11 Apr 2022 (T+90)
2,600 shares@ US$9.762157.4% of flowCommon StockSEC:0000899243-21-049429:0
Canonical exit: 21 Mar 2022 (T+90)
1,970.036 shares@ US$10.152164.7% of flowCommon StockSEC:0000899243-21-049427:0
Canonical exit: 21 Mar 2022 (T+90)
1,615,427 sharesCommon StockSEC:0001395064-21-000203:0
625 shares@ US$16.0010.4% of flowCommon StockSEC:0000899243-21-040253:0
Canonical exit: 10 Jan 2022 (T+90)
15,777,018 sharesCommon StockSEC:0000899243-21-040254:0
349,320 sharesCommon StockSEC:0000899243-21-040255:0
25 of 27 declarations
About Theseus Pharmaceuticals, Inc.
Theseus Pharmaceuticals, Inc. (THRX) was a U.S.-based biopharmaceutical company that traded on the NASDAQ market in the United States. Its business profile was squarely within healthcare and pharma, with a clinical-stage biotechnology model focused on the discovery, development, and eventual commercialization of transformative targeted cancer therapies. SEC filings describe Theseus as a clinical-stage company dedicated to improving outcomes for cancer patients through novel targeted therapies, which places it in the high-risk, high-upside segment of oncology biotech rather than in a diversified pharmaceutical model. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1745020/000174502023000080/thrx-20230930.htm?utm_source=openai))
From an analytical perspective, Theseus was not a broad commercial drug company but a focused research-and-development biotech built around a small number of oncology programs. That business model typically depends on scientific validation, clinical milestones, regulatory progress, and external financing rather than on current product sales. As a result, the investment case was driven more by platform quality, target differentiation, and trial execution than by revenue scale or market share. In other words, Theseus represented a classic development-stage life sciences story: potentially significant value creation if the science worked, but substantial dilution and binary clinical risk along the way. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1745020/000174502023000080/thrx-20230930.htm?utm_source=openai))
Read moreShow less
The company was headquartered in Cambridge, Massachusetts, placing it in one of the most important biotech clusters in the United States. That location matters strategically: Cambridge provides access to scientific talent, research institutions, specialist advisors, and a dense network of biopharma investors and collaborators. For a company like Theseus, being embedded in that ecosystem was an important competitive advantage, especially for recruiting, partnering, and fundraising. The company’s SEC history and insider filings also show that it operated as a closely watched public biotech name, which is typical for a development-stage issuer with limited commercial visibility and a valuation anchored to pipeline execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1792204/0001209191-23-000204-index.htm?utm_source=openai))
In terms of recent major developments, the defining event was the merger with Concentra Biosciences, LLC. SEC documents show that Theseus signed a merger agreement on December 22, 2023, and that the acquisition was completed on February 14, 2024. The transaction structure included cash consideration and a contingent value right (CVR), which is a common feature in biotech dealmaking when there is uncertainty around future asset value. For investors, this is crucial context: THRX is no longer a standard operating public equity story, because the company was taken private through that transaction and its stock ceased to be an ordinary NASDAQ-listed vehicle. Any current reference to THRX is therefore mainly relevant for historical analysis, transaction review, and legacy asset tracking rather than for ongoing public-market fundamentals. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1745020/000110465924023123/tm244360d5_sc14d9a.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
